MGMT and central nervous system cancer: A hypothetical patient received radiotherapy (score: 0), underwent chemotherapy (score: 0), was diagnosed with WHO Grade III glioma (score: 60.5), had IDH wildtype status (score: 31.9), MGMT promoter methylation (score: 0), 1p/19q codeletion (score: 0), age 55 years (score: 24), and high CD9 expression (>236.92, score: 21.9).